Home › Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration
 

Keywords :   


Agios Pharmaceuticals Exercises Option To U.S. Development And Commercialization Rights For IDH1 Program Under Celgene Collaboration

2014-02-05 07:17:03| drugdiscoveryonline News Articles

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, recently announced that it has elected to retain the United States development and commercial rights to the isocitratedehydrogenase 1 (IDH1) program including the clinical candidate AG-120, in accordance with the terms of its global strategic collaboration with Celgene Corporation in the field of cancer metabolism

Tags: rights under development program

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Cool Roof Coatings Market to Reach US$9.2B by 2030: Fairfield
26.06LG and Blacknut provide cloud video games through webOS
26.06Universal UK resort to open 365 days a year
26.06Steelwork closures' ripple effect on town's wages
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06VW to invest up to $5bn in Tesla rival Rivian
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
More »